We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+6.64%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.24%
AUM
$13.4B
AUM Growth
+$421M
(+3.2%)
Cap. Flow
-$231M
Cap. Flow
% of AUM
-1.73%
Top 10 Holdings %
Top 10 Hldgs %
18.95%
Holding
286
New
38
Increased
90
Reduced
103
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$95.8M |
| 2 |
Mettler-Toledo International
MTD
|
+$89.4M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$66.9M |
| 4 |
Carnival Corporation Ltd
CCL
|
+$64.4M |
| 5 |
Walt Disney
DIS
|
+$62.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Steris
STE
|
+$102M |
| 2 |
Abbott
ABT
|
+$97.9M |
| 3 |
MGM Resorts International
MGM
|
+$97.5M |
| 4 |
Bank of America
BAC
|
+$90.9M |
| 5 |
Philip Morris
PM
|
+$88.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.01% |
| 2 | Healthcare | 16.54% |
| 3 | Industrials | 13.55% |
| 4 | Financials | 11.42% |
| 5 | Consumer Discretionary | 11.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Hamilton Lane
HLNE
$5.61B
| $13M | 0.1% |
270,918
-1,542
| -0.6% | -$67.8K |
|
|
CBAY
202
DELISTED
Cymabay Therapeutics
CBAY
| $12.3M | 0.09% |
+915,220
| New | +$11.5M |
|
203
MGP Ingredients
MGPI
$366M
| $12.1M | 0.09% |
+136,510
| New | +$12.2M |
|
|
EVHC
204
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $10.8M | 0.08% |
246,315
-674,110
| -73% | -$27.7M |
|
205
Fate Therapeutics
FATE
$307M
| $9.13M | 0.07% |
+805,460
| New | +$8.87M |
|
|
206
Abbott
ABT
$183B
| $8.69M | 0.06% |
142,430
-1,614,408
| -92% | -$97.9M |
|
207
Walmart Inc
WMT
$883B
| $8.62M | 0.06% |
302,070
+53,475
| +22% | +$1.52M |
|
208
Texas Instruments
TXN
$258B
| $8.56M | 0.06% |
77,660
+830
| +1% | +$89.8K |
|
|
HF
209
DELISTED
HFF Inc.
HF
| $8.42M | 0.06% |
+245,216
| New | +$9.37M |
|
210
Occidental Petroleum
OXY
$54.8B
| $8.22M | 0.06% |
98,195
+980
| +1% | +$78.3K |
|
211
Conagra Brands
CAG
$7.19B
| $7.96M | 0.06% |
222,675
+43,590
| +24% | +$1.62M |
|
212
JPMorgan Chase
JPM
$956B
| $7.17M | 0.05% |
68,830
+940
| +1% | +$103K |
|
213
Verizon
VZ
$195B
| $7.05M | 0.05% |
140,160
+28,506
| +26% | +$1.38M |
|
214
Jack Henry & Associates
JKHY
$11.1B
| $6.64M | 0.05% |
50,949
+530
| +1% | +$65.8K |
|
215
Citizens Financial Group
CFG
$31.3B
| $6.23M | 0.05% |
160,070
+2,250
| +1% | +$93.7K |
|
216
Suncor Energy
SU
$76.3B
| $6.05M | 0.05% |
+148,805
| New | +$5.8M |
|
217
Caterpillar
CAT
$407B
| $5.69M | 0.04% |
41,940
+11,020
| +36% | +$1.65M |
|
218
Royal Caribbean
RCL
$87.2B
| $5.53M | 0.04% |
53,415
+760
| +1% | +$83.5K |
|
219
Delta Air Lines
DAL
$61.1B
| $5.41M | 0.04% |
+109,095
| New | +$5.82M |
|
220
NextEra Energy
NEE
$181B
| $5.26M | 0.04% |
125,960
+26,480
| +27% | +$1.07M |
|
|
ANDX
221
DELISTED
Andeavor Logistics LP
ANDX
| $5.24M | 0.04% |
+123,275
| New | +$5.51M |
|
222
Archer Daniels Midland
ADM
$38.2B
| $4.57M | 0.03% |
99,730
+1,470
| +1% | +$66K |
|
223
Danaher
DHR
$139B
| $3.78M | 0.03% |
43,193
-3,546
| -8% | -$316K |
|
|
224
Bank of America
BAC
$442B
| $2.8M | 0.02% |
99,410
-3,045,373
| -97% | -$90.9M |
|
225
Marten Transport
MRTN
$1.22B
| $2.3M | 0.02% |
147,249
| – | – |
|
Similar funds
OAG
JG
CHP
SC
Westfield Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Westfield Capital Management held 286 positions worth $13.4B, up 3.2% from $13B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Westfield Capital Management's Q2 2018 filing shows 38 new, 90 increased, 103 reduced and 43 closed positions. Its largest new stake was Bristol-Myers Squibb: 1,238,227 shares worth $68.5M. The largest sale was Steris, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Healthcare and Industrials.
- Westfield Capital Management's largest Q2 2018 buy was Bristol-Myers Squibb: 1,238,227 shares worth $68.5M.
- Westfield Capital Management added most to Thermo Fisher Scientific in Q2 2018, an estimated $95.8M increase.
- Westfield Capital Management's biggest Q2 2018 reduction was Steris, cutting an estimated $102M.
- Westfield Capital Management fully exited MGM Resorts International in Q2 2018, selling an estimated $97.5M.
- Westfield Capital Management's ten largest holdings make up 19% of its $13.4B portfolio in Q2 2018.
- Westfield Capital Management opened 38 new positions and closed 43 in Q2 2018.
- Westfield Capital Management's portfolio value rose 3.2% quarter-over-quarter to $13.4B.
Based on Westfield Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.